VEGFA and COVID-19: In our study, we showed firstly that, regardless of baseline clinical severity, plasma concentrations of numerous biomarkers characterizing coagulation/endothelial activation (i.e. D-dimers, vWF-A2, sICAM1, sTREM1, VEGF) or platelet activation (sP-selectin) were elevated in both groups, but lower in COVID-19 compared to non-COVID-19 patients.